"10.1371_journal.pone.0152480","plos one","2016-04-07T00:00:00Z","Ian Tagge; Audrey Oâ€™Connor; Priya Chaudhary; Jim Pollaro; Yosef Berlow; Megan Chalupsky; Dennis Bourdette; Randy Woltjer; Mac Johnson; William Rooney","Advanced Imaging Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States of America; Biomedical Engineering, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States of America; Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States of America; Pathology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States of America; Portland VA Medical Center, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, United States of America; Vertex Pharmaceuticals Incorporated, 50 Northern Ave, Boston, MA 02210, United States of America","Conceived and designed the experiments: WR IT MJ DB MC RW. Performed the experiments: IT JP AO PC MC RW. Analyzed the data: IT PC YB RW. Contributed reagents/materials/analysis tools: IT JP MJ PC RW. Wrote the paper: IT WR PC DB MJ YB RW.","Mac Johnson is a paid employee of and stockholder in Vertex Pharmaceuticals, Inc., a funder of this study. Vertex Pharmaceutical, Inc. funded this study as an investigation into the utility of MTR as an in-vivo biomarker of myelin content unrelated to any proprietary or investigational compounds or materials. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","04","Ian Tagge","IT",10,TRUE,6,6,4,7,TRUE,TRUE,FALSE,0,NA,FALSE
